What is it about?
In veterinary medicine, a method called "liquid biopsy" for detecting tumor-derived genes circulating in the bloodstream has not been established. We found that mutated gene can be detected in plasma samples of dogs with urothelial carcinoma harboring the BRAF V595E mutation using allele-specific real-time PCR. This technique may be useful for monitoring disease progression and treatment response.
Featured Image
Photo by Marcus Wallis on Unsplash
Why is it important?
Tumor monitoring in dogs with CT scans is costly and requires general anesthesia. Our research indicates that it is possible to detect tumor-derived genes that circulate in the blood even in dogs, and that monitoring these genes may make it possible to easily predict treatment response and prognosis.
Perspectives
We aim to develop "liquid biopsy" in veterinary medicine. This paper demonstrates the presence of circulating tumor DNA in dogs as well as in humans. We hope that this report will contribute to better management of neoplastic diseases in dogs and the well-being of dogs and their owners.
Michihito Tagawa
Okayama Rika Daigaku
Read the Original
This page is a summary of: Quantitative analysis of the BRAF V595E mutation in plasma cell-free DNA from dogs with urothelial carcinoma, PLoS ONE, April 2020, PLOS,
DOI: 10.1371/journal.pone.0232365.
You can read the full text:
Resources
Contributors
The following have contributed to this page
